Xipere
Customize your policy alerts
Sign up for Cigna Policy IP0371 alerts
Get alerted when Policy IP0371 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical necessity coverage for Xipere for macular edema associated with non-infectious uveitis under Cigna-administered commercial health benefit plans.
The policy added an adult age requirement for Xipere coverage.
The policy added continuation-of-therapy criteria for patients currently receiving Xipere.
The policy added specific dosing criteria for Xipere.
Concomitant use of Xipere with another intravitreal corticosteroid was added as not medically necessary.
The preferred product requirement was revised to require a trial of Triesence ophthalmic injectable suspension.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.